Company news

Amneal Pharmaceuticals, Inc. news in 2024

Amneal Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

November 20, 2024

Amneal Reports Third Quarter 2024 Financial Results

November 7, 2024

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

October 20, 2024

Amneal to Report Third Quarter 2024 Results on November 8, 2024

October 7, 2024

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

September 30, 2024

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease

September 22, 2024

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

September 4, 2024

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

August 19, 2024

Amneal Reports Second Quarter 2024 Financial Results

August 8, 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

August 6, 2024

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

July 28, 2024

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

July 8, 2024

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

June 30, 2024

Amneal Releases 2023 Environmental, Social and Governance Report

June 27, 2024

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

June 4, 2024

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

May 21, 2024

Amneal Reports First Quarter 2024 Financial Results

May 2, 2024

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

April 23, 2024

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

April 15, 2024

Amneal to Report First Quarter 2024 Results on May 3, 2024

April 9, 2024

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

March 24, 2024

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

February 26, 2024

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application

February 7, 2024

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

January 30, 2024

Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension

January 9, 2024

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

January 3, 2024

Calls in 2024

Decks in 2024